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Abstract
Background: Elderly patients are underrepresented in clinical trials but comprise the majority of heart failure patients.
Data on age-specific use of heart failure therapy are limited. The European Society of Cardiology heart failure guidelines
provide no age-specific treatment recommendations. We investigated practice-based heart failure management in a large
registry at heart failure outpatient clinics.
Design and methods: We studied 8351 heart failure with reduced ejection fraction patients at 34 Dutch outpatient
clinics between 2013 and 2016. The mean age was 72.3 11.8 years and we divided age into three categories: less than
60 years (13.9%); 60–74 years (36.0%); and 75 years and over (50.2%).
Results: Elderly heart failure with reduced ejection fraction patients (75 years) received significantly fewer beta-
blockers (77.8% vs. 84.2%), renin–angiotensin system inhibitors (75.2% vs. 89.7%), mineralocorticoid receptor antagon-
ists (50.6% vs. 59.6%) and ivabradine (2.9% vs. 9.3%), but significantly more diuretics (88.1% vs. 72.6%) compared to
patients aged less than 60 years (Pfor all trends< 0.01). Moreover, the prescribed target dosages were significantly lower in
elderly patients. Also, implantable cardioverter defibrillator (18.9% vs. 44.1%) and cardiac resynchronisation therapy
device (14.6% vs. 16.7%) implantation rates were significantly lower in elderly patients. A similar trend in drug prescrip-
tion was observed in patients with heart failure with mid-range ejection fraction as in heart failure with reduced ejection
fraction.
Conclusion: With increasing age, heart failure with reduced ejection fraction patients less often received guideline-
recommended medication prescriptions and also in a lower dosage. In addition, a lower percentage of implantable
cardioverter defibrillator and cardiac resynchronisation therapy device implantation in elderly patients was observed.
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Introduction
Chronic heart failure (HF) is a major healthcare prob-
lem, associated with a poor prognosis, high morbidity
and mortality.1 Optimising medical and device therapy
according to the guidelines improves prognosis.2
Therefore, adherence to the guidelines, such as the
rate of drug prescription and dosage, are often used
as benchmarks of quality of care. Approximately
1–2% of the global adult population is diagnosed
with HF.3 Due to an aging population and better sur-
vival of underlying heart diseases, these numbers are
expected to rise even further.4 Elderly patients are a
major part of the HF population, with approximately
80% older than 65 years, and 40–50% even aged
75 years or older.2,5
In elderly patients, HF is the leading cause of hos-
pitalisation and is associated with high morbidity and
mortality, resulting in an enormous burden on hospital
resources.6 Due to the high prevalence of comorbidities
in elderly patients, optimising HF management remains
even more challenging.7 Until now, randomised clinical
trials investigating HF therapy did not include large
number of elderly patients,8 with the exception of the
SENIORS trial.9 In fact, patients enrolled in these trials
were on average 10 years younger than in daily clinical
practice,3 and elderly patients were clearly underrepre-
sented.10 A few registries have shown a lower prescrip-
tion rate in the elderly but lack size.8,11 Despite the
ongoing discussion on optimal therapy in elderly HF
patients, there is no European Society of Cardiology
(ESC) recommended age-speciﬁc guidelines for HF
treatment,2 and data in groups of patients with
advanced age are scarce.
Therefore, we investigated age-related diﬀerences in
HF therapy in a large-scale cross-sectional registry in
34 Dutch HF clinics, reﬂecting actual practice-based
HF care at outpatient clinics including large numbers
of elderly patients.
Methods
The design and methods of the CHECK–HF
(Chronisch Hartfalen ESC – richtlijn Cardiologische
praktijk Kwaliteitsproject HartFalen) registry have
been published in detail elsewhere.12,13 Brieﬂy, the
CHECK–HF registry consists of 10,910 patients with
chronic HF from a total of 34 participating Dutch cen-
tres, participating in the inclusion for this cross-
sectional observational cohort. Between 2013 and
2016, all centres included patients diagnosed with HF
according to 2012 ESC guidelines on HF,2 based on
symptoms and echo parameters, who were seen at the
outpatient HF clinic (96%) or general cardiology out-
patient clinic (4%) if no speciﬁc HF clinic was present.
Baseline patient characteristics, aetiology of HF,
comorbidities, basic echocardiographic and electrocar-
diographic parameters, laboratory markers, pace-
maker, implantable cardioverter deﬁbrillator (ICD)
and cardiac resynchronisation therapy (CRT) treat-
ment, as well as prescription rates of medication
(drug name, dosage and frequency and total daily
dose), were recorded. Furthermore, contraindication
and intolerance rates were collected.
Ivabradine was only considered indicated on top of
optimal treatment with beta-blockers, angiotensin-con-
verting enzyme inhibitors (ACEIs) (or angiotensin II
receptor blockers (ARBs)) and mineralocorticoid
receptor antagonists (MRAs) (or ARBs), and if
patients were in sinus rhythm, left ventricular ejection
fraction (LVEF) of 35% or less, heart rate of 70 beats/
minute or greater and were still symptomatic
(New York Heart Assocation (NYHA) II), or already
received ivabradine. Target doses of guideline-recom-
mended HF therapy are presented in Supplementary
Table 1.
Based on echocardiographic results, patients were
classiﬁed based on LVEF or visual assessment of the
function of the left ventricle function as heart failure
with reduced ejection fraction (HFrEF, LVEF <50%
(n¼ 8360 (76.6%))), and according to 2016 ESC HF
guidelines as heart failure with mid-range ejection frac-
tion (HFmrEF) (LVEF 40–49% (n¼ 1574 (14.4%))) in
those with available measurement of ejection fraction.
In addition, HFpEF was classiﬁed as LVEF of 50% or
greater in 2267 (20.8%) patients. In 274 (2.5%)
patients, recording of the left ventricular function in
the database was insuﬃcient to classify patients into
HF type, in nine patients (0.1%) age was missing in
the database, and they were excluded from this ana-
lysis. In the current analyses, we focus on age-related
treatment diﬀerences in guideline recommended HF
therapies, including device therapy and lifestyle inter-
ventions, in HFrEF and HFmEF patients only.
Statistical analysis
Continuous data are expressed as mean valueSD or
median and interquartile range, depending on the dis-
tribution of the data, and compared by the one-way
analysis of variance (ANOVA) or Mann–Whitney
U-test. Categorical data are expressed as counts and
percentages, and compared by the Pearson chi-square
test. In order to investigate whether the observed age-
related diﬀerences were independent of potential clin-
ical predictors, univariable and multivariable logistic
regression were used. Results of these regression ana-
lyses are expressed as odds ratios (ORs) with 95% con-
ﬁdence intervals (CIs). A two-sided P value of 0.05 was
considered statistically signiﬁcant.
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In model 1, we adjusted for gender only. In model 2,
we further adjusted for NYHA and LVEF. In model 3,
we further included all comorbidities which were sig-
niﬁcantly related to the outcome variable at statistical
level P value less than 0.05 using stepwise entry method
in binary logistic regression. In the speciﬁc device ther-
apy-related analysis, QRS duration was an additional
variable in univariable analysis we included by entry
method in the models. Age was entered per 10 years
into the models.
In a total of 8.9% of all predicting values data were
missing. These missing data were imputed using mul-
tiple imputation. If the missing variables showed a
monotone pattern of missing values, the monotone
method was used, otherwise, an iterative Markov
chain Monte Carlo method was used with a number
of 10 iterations. A total of ﬁve imputations was per-
formed, and the pooled data were analysed. The
imputed data were only used for the multivariable ana-
lysis. For all reported data of the multivariable ana-
lysis, we compared crude and imputed P values as
well as the ORs and CIs in order to analyse whether
imputation changed the results, and if no signiﬁcant
changes occurred we only presented the imputed
values in the main analyses. All analyses were per-
formed with SPSS statistical package version 24.0
(SPSS Inc., Chicago, IL, USA).
Results
HFrEF patients (n¼ 8351) were on average 72.3 11.8
years old, with 13.9% less than 60 years of age, 36.0%
between 60 and 74 years, and 50.2% 75 years or older;
63.9% were men. Most patients were in NYHA class II
and approximately half of the patients had an ischae-
mic cause of their HF (Table 1).
Elderly HFrEF patients had signiﬁcantly more renal
insuﬃciency, more often atrial ﬁbrillation, thyroid dis-
ease, chronic obstructive pulmonary disease, diabetes
mellitus and hypertension and less often obstructive
sleep apnoea syndrome when compared to younger
patients (P< 0.01, for all) (Table 1).
Pharmacological therapy in HFrEF
Elderly patients less often received beta-blockers,
renin–angiotensin system (RAS) inhibitors, MRAs
and ivabradine, but signiﬁcantly more diuretics than
younger patients (Table 2). These diﬀerences gradually
increased with age.
Patients received all three of the HF medications
(beta-blockers, RAS inhibitors and MRAs), if indi-
cated, in 47.8%, 38.7% and 29.6% of the patients
in the three age groups (<60 years, 60–74 years and
75 years, respectively), two out of three were
prescribed in 39.9%, 45.4% and 47.6%, one out of
three was prescribed in 10.2%, 14.0% and 19.5%,
and none of these medications were prescribed
in 2.1%, 1.9% and 3.3%, respectively (P< 0.01).
Supplementary Figure 1 shows the use of RAS inhibi-
tors divided into ACEIs and ARBs.
The total reported contraindication or intolerance
rates were 3.2% (beta-blockers), 4.6%, (RAS inhibi-
tors), 4.7% (MRAs) and 1.7% (ivabradine) (Table 3).
The reported contraindication or intolerance rates in
elderly patients were signiﬁcantly higher for beta-block-
ers, RAS inhibitors and MRAs (P< 0.01). However, in
a substantial number of patients the reason for not
receiving RAS inhibitors or MRAs was not speciﬁed
in the patients’ charts.
Elderly patients less often received the recom-
mended target dose of beta-blockers, RAS inhibitors
and MRAs than the younger patient groups
(P< 0.01, for all) (Figure 1). Fifty per cent or greater
of the target dose of all three of the HF medication
groups (beta-blockers, RAS inhibitors and MRAs)
was achieved in 25.4%, 17.7% and 11.0% of the
patients (<60 years, 60–74 years and 75 years,
respectively); 50% or greater of the target dose of two
out of three medications in 38.6%, 40.6% and 35.7%,
respectively; 50% or greater of the target dose of none
out of three medication in 27.1%, 32.2% and 38.3%,
respectively. Younger patients more often received 50%
or greater of the target dose of all three guideline-
recommended medications than elderly patients,
P< 0.01.
After multivariable adjustment, the probability of
receiving a beta-blocker, RAS inhibitor, MRA and
ivabradine decreases for each 10-year increase
in age by 10% (MRAs), 12% (beta-blockers), 29%
(RAS inhibitors) and 21% (ivabradine), whereas the
probability of receiving diuretics increases by 32%
(Table 4). Multiple imputation did not change these
ﬁndings. The age diﬀerences in HF therapy, adjusted
for the diﬀerences in comorbidities, are presented in
Table 4.
The percentage of ﬂuid and sodium restriction
recommendations are presented in Supplementary
Figure 2.
Device implantation in HFrEF
Elderly patients received signiﬁcantly more pace-
makers, but fewer ICD and CRT devices, compared
to younger patients (Table 2). After adjustment for
multiple clinical parameters, the chance of receiving
an ICD and CRT device decreases by 39% and 17%,
respectively, for every 10-year increase in age (Table 4).
After multiple imputation, the described diﬀerences did
not change.
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General therapy in subgroups of HFmrEF
HFmrEF patients were on average 73.7 11.7 years
old, and 58.4% were men. The diﬀerences in baseline
characteristics between HFrEF and HFmrEF patients
are shown in Supplementary Table 2. Beta-blockers
(82.3% vs. 74.7%, P< 0.01), RAS inhibitors (88.0%
vs. 71.9%, P< 0.01) and ivabradine (5.9% vs. 2.1%,
P¼ 0.02) were less often prescribed in patients aged
75 years and older compared to patients less than
60 years, while MRAs (35.4% vs. 46.0%, P¼ 0.02)
and diuretics (55.4% vs. 86.6%, P< 0.01) were more
often prescribed (Table 2). The inferences of the
HFmrEF group are comparable to the ﬁndings in
HFrEF.
Discussion
This large practice-based clinical registry of 8351 HF
patients including a relatively large group of elderly
Table 1. Patient characteristics in HFrEF patients.
HFrEF (n¼ 8351)z
Age <60 years
(n¼ 1206)
Age 60–74 years
(n¼ 3105)
Age 75 years
(n¼ 4040) P value
Age (years) 51.3 7.1 68.0 4.2 81.8 4.7 <0.01
Male gender 763 (63.6) 2163 (70.0) 2388 (59.3) <0.01
BMI, kg/m2 28.7 6.1 27.9 5.4 26.2 4.4 <0.01
NYHA
I 322 (26.9) 569 (18.5) 421 (10.6) <0.01
II 667 (55.7) 1845 (60.0) 2176 (54.6)
III 192 (16.0) 618 (20.1) 1295 (32.5)
IV 16 (1.3) 42 (1.4) 91 (2.3)
LVEF, % 30.4 10.4 31.6 10.0 34.2 10.8 <0.01
Cause of HF
Ischaemic cause of HF 435 (37.1) 1630 (54.0) 2113 (54.3) <0.01
Non-ischaemic cause of HF 738 (62.9) 1390 (46.0) 1779 (45.7)
Systolic BP, mmHg 123.1 20.0 126.2 20.6 126.0 20.9 <0.01
Diastolic BP, mmHg 74.3 11.5 72.5 11.2 69.3 11.1 <0.01
Heart rate, bpm 72.8 13.8 71.8 14.2 71.9 13.6 0.09
Atrial fibrillation 87 (7.3) 678 (22.1) 1341 (33.6) <0.01
LBBB 156 (12.9) 490 (15.8) 767 (19.0) <0.01
QRS 130 ms 289 (27.8) 957 (37.2) 1525 (46.0) <0.01
eGFR, ml/min 79.3 22.8 64.8 23.6 50.8 21.6 <0.01
eGFR
<30 ml/min 23 (3.0) 154 (7.1) 490 (16.5) <0.01
30–59 ml/min 116 (15.2) 774 (35.8) 1552 (52.4)
60 ml/min 622 (81.7) 1,231 (57.0) 921 (31.1)
Comorbidities
Hypertension 306 (29.1) 1097 (39.4) 1573 (43.2) <0.01
Diabetes mellitus 252 (23.9) 848 (30.4) 1072 (29.4) <0.01
COPD 118 (11.2) 546 (19.6) 717 (19.7) <0.01
OSAS 95 (9.0) 246 (8.8) 154 (4.2) <0.01
Thyroid disease 57 (5.4) 209 (7.5) 290 (8.0) 0.02
Renal insufficiencyy 191 (20.3) 1214 (47.1) 2543 (72.9) <0.01
HFrEF: heart failure with reduced ejection fraction; BMI: body mass index; NYHA: New York Heart Association classification; LVEF: left ventricular
ejection fraction; HF: heart failure; BP: blood pressure; LBBB: left bundle branch block; eGFR: estimated glomerular filtration rate; COPD: chronic
obstructive pulmonary disease; OSAS: obstructive sleep apnoea syndrome.
yDefined as eGFR <60 mL/min or a history of renal failure.
zIn nine patients data on age were missing.
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patients demonstrates that aged HFrEF patients less
often receive guideline-recommended therapy.
Furthermore, the prescribed dosages as a percentage
of the target dose, especially to elderly patients, are
lower than recommended.
Pharmacological therapy
Previous recent large registries demonstrated an age-
related decline of ESC HF guidelines recommended
HF therapy, especially in patients older than
75 years.11,14–17 However, these registries are older
and were not using the ESC HF guidelines of 2012.
Our results also demonstrate an age-related decline,
but in contrast to these earlier registries, the decline
in our study started already in patients older than 60
years of age and seems to be continuous, indicating that
the decline is not restricted to the very old.
It has been suggested that the higher rate of comor-
bidities or the diﬀerent aetiology of HF might be an
explanation for the age-associated decline in drug pre-
scription.16 Although we demonstrated signiﬁcant dif-
ferences in comorbidities between age groups, these
diﬀerences were not large enough to explain the
observed diﬀerences in prescription rates as shown in
our multivariable analysis. In chronic HF patients,
chronic obstructive pulmonary disease frequently coex-
ists and symptoms overlap, and while getting more
prevalent with increasing age, adequate treatment of
underlying diseases gets even more challenging.18
Frailty in elderly patients is highly prevalent and is
associated with a worse prognosis19 and might explain
in some part the lower prescription rate in elderly
patients; however, this could not be tested in our regis-
try as no information on frailty was available.
Although elderly patients constitute a large part of
the general HF population, patients aged 75 years of
age and older are underrepresented in large randomised
clinical trials.2,5,11 Thereby the positive eﬀect of the HF
medication in the elderly HF population is not yet
properly investigated. This might be another explan-
ation for the decline in prescription rates in elderly
patients. However, the decline appears to be not limited
to the very old, but to be a continuum, starting at a
younger age than was previously assumed, indicating
that the decline cannot be fully explained by lack of
evidence in the elderly alone.
In contrast to the HF medication, diuretics, ﬂuid and
sodium restrictions are more often used in elderly
patients. However, after adjustment in the multivari-
able analysis for comorbidities, the inﬂuence of
age is largely reduced, in contrast to the other
Table 2. Percentage of HF therapy use in HFrEF and HFmrEF patients.
Pharmacotherapy Device therapy
Beta-blockers RAS inhibitors MRAs Ivabradine* Diuretics ICD CRT Pacemaker
ESC Guideline 2012
HFrEF
<60 Years 978 (84.2) 1042 (89.7) 692 (59.6) 112 (9.3) 843 (72.6) 417 (44.1) 158 (16.7) 13 (1.4)
60–74 Years 2492 (81.5) 2627 (85.9) 1639 (53.6) 153 (4.9) 2440 (79.8) 1018 (41.2) 500 (20.2) 102 (4.1)
75 Years 3103 (77.8) 2999 (75.2) 2017 (50.6) 119 (2.9) 3,513 (88.1) 612 (18.9) 473 (14.6) 446 (13.8)
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
ESC Guideline 2016
HFrEF
<60 Years 834 (84.5) 888 (90.0) 630 (63.8) 101 (9.9) 746 (75.7) 385 (45.9) 145 (17.3) 9 (1.1)
60–74 Years 2073 (81.5) 2209 (86.9) 1397 (55.0) 133 (5.2) 2048 (80.6) 950 (44.7) 463 (21.8) 82 (3.9)
75 Years 2473 (78.6) 2393 (76.1) 1629 (51.8) 101 (3.2) 2783 (88.5) 565 (21.8) 428 (16.5) 335 (12.9)
P value <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
HFmrEF
<60 Years 144 (82.3) 154 (88.0) 62 (35.4) 11 (5.9) 97 (55.4) 32 (29.9) 13 (12.1) 4 (3.7)
60–74 Years 419 (81.0) 418 (80.9) 242 (46.8) 20 (3.8) 392 (76.0) 68 (19.8) 37 (10.8) 20 (5.8)
75 Years 630 (74.7) 606 (71.9) 388 (46.0) 18 (2.1) 730 (86.6) 47 (7.2) 45 (6.9) 111 (17.0)
P value <0.01 <0.01 0.02 0.02 <0.01 <0.01 0.05 <0.01
CRT: cardiac resynchronisation therapy; ESC: European Society of Cardiology; HF: heart failure; HFrEF: heart failure with reduced ejection fraction;
HFmrEF: heart failure with mid-range ejection fraction; ICD: implantable cardioverter defibrillator; MRAs: mineralocorticoid receptor antagonists;
RAS: renin–angiotensin syndrome.
*If ivabradine is indicated (n¼ 500), patients with HFrEF according to the 2012 ESC Guideline received 78.3%, 75.0% and 77.8% (<60, 60–74 and 75
years, respectively, P¼ 0.73) ivabradine.
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recommendations. This might indicate that the use of
diuretics, ﬂuid and sodium restrictions can partially be
explained by worse renal function in elderly patients.
Despite the fact that elderly patients less often
received guideline-recommended pharmacological ther-
apy, we still observed an overall high prescription rate
in all age groups, compared to the CHAMP–HF regis-
try.20 Importantly, when HF medication is prescribed,
the actual dosages are signiﬁcantly lower in elderly than
in younger patients, which could potentially lead to a
worse outcome. As has been shown, good adherence to
the guidelines, with prescription of at least 50% of the
recommended dosage, is associated with better clinical
outcomes.21
Despite relative good guideline adherence, there still
seems to be room for further improvement, especially in
the prescribed dosages, and in the elderly population.
As previously demonstrated, the uptitration of HF
medication is possible, even in elderly patients.22
However, evidence on the eﬀect of HF therapy in
patients aged 75 years and older is very limited,22,23
and appropriate prospective trials are urgently needed
to address the important question as to whether treat-
ment should diﬀer depending on age.
Device therapy
Elderly patients less often received a ICD or CRT
device, and more frequently received a pacemaker.
These results are in line with recent publications, show-
ing a decline of the CRT device and ICD implantation
rate in older patients11,14,16 and an increase of the pace-
maker implantation rate.11
The age diﬀerences in implantation rates might be
explained by more perceived or actual comorbidities or
contraindications, including non-HF-related comorbid-
ities such as cognitive and mobility impairments.16 It
has been shown that elderly HF patients have a higher
non-cardiac mortality rate compared with younger HF
patients.24 This might negatively inﬂuence the beneﬁts
and cost-eﬀectiveness of implanted devices in the eld-
erly. However, after multivariable analysis, the age-
related diﬀerences remained. Also, device implantation,
such as ICDs, has been shown to be eﬀective and even
warranted in elderly patients if life expectancy is longer
than one year.24 Still, a recent study in patients with non-
ischaemic cardiomyopathy found a strong relationship
between reduced mortality by ICD and age, with only
younger patients having any beneﬁt in post-hoc ana-
lysis.25 Furthermore, assumption of a higher risk of com-
plications due to the implantation procedure in elderly
patients might explain the lower implantation rates.
However, as recently reported there are no diﬀerences
in the number of complications in elderly patients com-
pared with younger patients.26 Finally, the perception
that quality of life is seen as more important for elderly
patients than a prolonged survival period might result in
the lower implantation rates of a ICD. However, the
preference of patients to prefer longevity over optimal
quality of life was found to be surprisingly high and not
individually predictable even at a high age.27
The use of a CRT device not only reduces morbidity
and mortality, but also symptoms and improves quality
of life, also in elderly patients.28 In addition, it can lead
to a rise in blood pressure and protect against brady-
cardia.29 These gains may lead to a better adherence to
recommended HF medication, such as beta-blockers.29
Thus, there is no evidence that a CRT device may be
less important in HFrEF patients at an older age. As
elderly patients are more often in need of a pacemaker,
as shown in our results, and a CRT device holds posi-
tive treatment eﬀects for elderly patients, it might be
beneﬁcial to treat these patients with biventricular
CRT pacing instead of right ventricular pacing using
a pacemaker.
Limitations and strengths
Our study has some limitations. CHECK–HF has a
cross-sectional design with no follow-up data on
Table 3. Reasons for not prescribing HF medication in HFrEF
patients.
Contraindicated
or intolerance
No reason
specified
Beta-blockers
Total population 262 (3.2) 971 (11.8)
<60 Years 21 (1.8) 109 (9.4)
60–74 Years 90 (2.9) 300 (9.8)
75 Years 150 (3.8) 562 (14.1)
RAS inhibitors
Total population 380 (4.6) 1161 (14.1)
<60 Years 21 (1.8) 99 (8.5)
60–74 Years 105 (3.4) 327 (10.7)
75 Years 254 (6.4) 735 (18.4)
MRAs
Total population 387 (4.7) 3479 (42.3)
<60 Years 25 (2.2) 445 (38.3)
60–74 Years 115 (3.8) 1305 (42.7)
75 Years 247 (6.2) 1724 (43.2)
Ivabradine*
Total population 143 (1.7) 7691 (93.6)
<60 Years 12 (1.0) 1038 (89.3)
60–74 Years 52 (1.7) 2854 (93.3)
75 Years 79 (2.0) 3790 (95.0)
HF: heart failure; HFrEF: heart failure with reduced ejection fraction.
*If indicated (n¼ 500) 22.6%, 23.5% and 22.2% (<60, 60–74 and
75 years, respectively) of patients did not receive ivabradine with no
specified reason.
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patient outcomes. In addition, for some important vari-
ables data were missing, which might inﬂuence the
results. However, imputation of missing data did not
inﬂuence the results. The strengths of the CHECK–HF
registry include the large scale, a reﬂection of the true
practice of outpatient HF management in The
Netherlands representative of western European coun-
tries. A further strength is the availability of a large
Table 4. Multivariable analysis: likelihood of receiving guideline recommended therapy per 10 years of age in patients with HFrEF.
Univariable Multivariable
Model 1 Model 2 Model 3
OR P value OR P value OR P value OR P value
Guideline recommended pharmacotherapy
Beta-blockers 0.87 (0.83–0.92) <0.01 0.87 (0.83–0.91) <0.01 0.88 (0.83–0.92) <0.01 0.83 (0.79–0.88) <0.01
RAS inhibitors 0.67 (0.64–0.71) <0.01 0.67 (0.64–0.71) <0.01 0.71 (0.67–0.75) <0.01 0.75 (0.71–0.80) <0.01
MRAs 0.93 (0.89–0.96) <0.01 0.93 (0.91–0.94) <0.01 0.90 (0.86–0.93) <0.01 0.86 (0.83–0.90) <0.01
Ivabradine* 0.72 (0.67–0.78) <0.01 0.72 (0.67–0.77) <0.01 0.69 (0.64–0.75) <0.01 0.69 (0.62–0.75) <0.01
Diuretics 1.42 (1.35–1.48) <0.01 1.41 (1.38–1.45) <0.01 1.32 (1.26–1.39) <0.01 1.15 (1.09–1.21) <0.01
Guideline recommended device therapy
ICD 0.63 (0.60–0.66) <0.01 0.63 (0.60–0.66) <0.01 0.61 (0.57–0.65) <0.01 0.62 (0.57–0.67) <0.01
CRT 0.88 (0.83–0.92) <0.01 0.88 (0.86–0.90) <0.01 0.83 (0.78–0.88) <0.01 0.75 (0.71–0.80) <0.01
Pacemaker 2.29 (2.07–2.53) <0.01 2.29 (2.17–2.41) <0.01 2.17 (1.94–2.41) <0.01 2.25 (2.00–2.53) <0.01
COPD: chronic obstructive pulmonary disease; CRT: cardiac resynchronisation therapy; eGFR: estimated glomerular filtration rate; HFrEF: heart failure
with reduced ejection fraction; ICD: implantable cardioverter defibrillator; MRAs: mineralocorticoid receptor antagonists; NYHA: New York Heart
Association; OR: odds ratio; OSAS: obstructive sleep apnoea syndrome; RAS: renin–angiotensin syndrome.
Model 1 included age and gender.
Model 2 included age, gender, NYHA classification, left ventricular ejection fraction (and QRS for device therapy).
Model 3 included age, gender, NYHA classification, left ventricular ejection fraction (QRS duration for device therapy), hypertension, diabetes mellitus,
COPD, OSAS, thyroid disease, renal insufficiency (defined as eGFR <60 mL/min or a history of renal insufficiency) and atrial fibrillation.
*For ivabradine atrial fibrillation was not included in the model; if ivabradine was indicated (n¼ 500) the ORs were 1.00 (0.85–1.18), 1.00 (0.92–1.09),
0.97 (0.82–1.15) and 0.97 (0.80–1.17) for univariable, model 1–3, respectively, P> 0.70.
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Figure 1. Percentages of target dose prescribed in heart failure with reduced ejection fraction.
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number of elderly patients with detailed information on
medication prescription and dosage.
Conclusion
In this large Dutch registry of a real-world outpatient
HF population, HFrEF patients in a higher age group
less often received guideline-recommended HF drugs,
at lower dosages and less often ICD and CRT device
therapy. The diﬀerences cannot be fully explained by
clinical variables, comorbidities or higher reported
contraindications or intolerance. Our study indicates
the need to focus especially on elderly HF patients, in
order to optimise their medical therapy, and further
uptitrate their dosages or reﬂect on policy and accept
lower age-adjusted target doses in elderly patients as
they do not tolerate higher dosages.
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